At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 37 enrolled
Drug / intervention
CP-675,206 (Tremelimumab)drug
Likely dose
CP-675,206 (Tremelimumab) 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Rollover Protocol For Patients Who Received Tremelimumab (CP-675,206 ) In Other Protocols
In Brief
A Phase 2 clinical trial evaluating CP-675,206 (Tremelimumab) for Colorectal Neoplasms and 5 related conditions. Completed, enrolled 37 participants across 6 sites in 2 countries.
Detailed Summary
This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Neoplasms, Melanoma, Prostatic Neoplasms, Renal Cell Carcinoma, Neoplasms, Patients Who Have/Have Had Melanoma and Other Tumors
CountriesUnited Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2006
Enrollment StartMar 2007
Primary CompletionOct 2023
TodayJul 2026
First PostedSep 20, 2006
Enrollment StartMar 5, 2007
Primary CompletionOct 27, 2023
TodayJul 2, 2026
Enrollment to primary: 16.6 yearsPosted 19.8 years ago
Interventions
CP-675,206 (Tremelimumab)drug
15 mg/kg IV every 3 months as long as required